PTK2 and cancer: The small molecule FAK inhibitor IN10018 was formerly developed by Boehringer‐Ingelheim (BI) under the name BI853520;[23] it is a highly selective clinical‐stage FAK inhibitor.[23, 24] Based on our analysis and other reports,[12, 14] we hypothesized that FAK inhibition by IN10018 may exert a good anticancer response to KRAS mutant cancer cells and tumors.